Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.42 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5868895 | 1.00 | AAK1 (0.48) | AAK1CYP17A1ABCB1ABCC1HDAC1 | |
| SCHEMBL20163070 | 0.90 | ABCB1 (0.56) | AAK1CYP17A1ABCB1ABCC1HDAC1 | |
| SCHEMBL30059279 | 0.88 | CYP17A1 (0.54) | AAK1CYP17A1ABCB1ABCC1HDAC1 | |
| SCHEMBL197036 | 0.88 | CYP17A1 (0.54) | AAK1CYP17A1ABCB1ABCC1HDAC1 | |
| SCHEMBL3790831 | 0.87 | AAK1 (0.47) | AAK1CYP17A1ABCB1ABCC1HDAC1 | |
| SCHEMBL5868898 | 0.87 | HDAC2 (0.50) | AAK1CYP17A1ABCB1ABCC1HDAC1 | |
| SCHEMBL1753916 | 0.87 | ABCB1 (0.54) | AAK1CYP17A1ABCB1ABCC1HDAC1 | |
| SCHEMBL5868802 | 0.87 | ABCB1 (0.54) | AAK1CYP17A1ABCB1ABCC1HDAC1 | |
| SCHEMBL25216132 | 0.86 | CYP17A1 (0.54) | AAK1CYP17A1ABCB1ABCC1HDAC1 | |
| Ammonia Solution, Strong SCHEMBL21835798 | 0.86 | ABCB1 (0.53) | AAK1CYP17A1ABCB1ABCC1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572368-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | AAK1 1755/4885CYP17A1 950/4885ABCB1 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.